Literature DB >> 9445131

Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology.

M Mandai1, I Konishi, H Kuroda, T Komatsu, S Yamamoto, K Nanbu, K Matsushita, M Fukumoto, H Yamabe, T Mori.   

Abstract

The carcinogenic process of epithelial ovarian carcinomas is still unknown, and both pathways of de novo carcinogenesis from the surface epithelium and malignant transformation of benign cystadenoma have been suggested. Especially in mucinous ovarian tumors, the transition from benign cystadenomas to tumors of low malignant potential (LMP) or carcinomas has been implicated. To elucidate this possibility, we analyzed the presence or absence of heterogeneity of the K-ras mutation corresponding to the histological heterogeneity in 71 epithelial ovarian tumors, including 31 mucinous tumors. K-ras mutation was identified in nine mucinous tumors (4 of 10 carcinomas, 4 of 14 LMP tumors, and 1 of 7 cystadenomas) and in two nonmucinous carcinomas. Microdissection of multiple sites with reference to their histological appearance showed the heterogeneous distribution of K-ras-mutated epithelia in two of the nine mucinous tumors. One mucinous carcinoma showed K-ras mutation in all of the histologically LMP and malignant portions, but not in benign portions. In another LMP tumor, all of the LMP portions and one of the benign portions showed K-ras mutation, whereas the other two benign portions had no mutation. In the remaining seven mucinous tumors with K-ras mutation, however, there was a homogeneous distribution of K-ras-mutated epithelia irrespective of their histological appearance. These findings suggest that the K-ras mutation occurs during the transformation from benign cystadenomas to LMP or malignant lesions, providing molecular genetic support for the hypothesis of the "adenoma-carcinoma sequence" in some mucinous ovarian tumors, but in other cases an alternative pathway may also be possible.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9445131     DOI: 10.1016/s0046-8177(98)90387-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  12 in total

Review 1.  Molecular pathogenesis of endometrial and ovarian cancer.

Authors:  Melissa A Merritt; Daniel W Cramer
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

2.  Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression.

Authors:  M Saegusa; D Machida; I Okayasu
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

Review 3.  Recent concepts of ovarian carcinogenesis: type I and type II.

Authors:  Masafumi Koshiyama; Noriomi Matsumura; Ikuo Konishi
Journal:  Biomed Res Int       Date:  2014-04-23       Impact factor: 3.411

Review 4.  The molecular background of mucinous carcinoma beyond MUC2.

Authors:  Niek Hugen; Michiel Simons; Altuna Halilović; Rachel S van der Post; Anna J Bogers; Monica Aj Marijnissen-van Zanten; Johannes Hw de Wilt; Iris D Nagtegaal
Journal:  J Pathol Clin Res       Date:  2014-11-05

5.  Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.

Authors:  Yi-Ju Lee; Ming-Yung Lee; Alexandra Ruan; Chi-Kuan Chen; Hao-Ping Liu; Chau-Jong Wang; Wan-Ru Chao; Chih-Ping Han
Journal:  Oncotarget       Date:  2016-12-13

Review 6.  Subtypes of Ovarian Cancer and Ovarian Cancer Screening.

Authors:  Masafumi Koshiyama; Noriomi Matsumura; Ikuo Konishi
Journal:  Diagnostics (Basel)       Date:  2017-03-02

Review 7.  Ovarian cancer: pathology, biology, and disease models.

Authors:  Daniel G Rosen; Gong Yang; Guangzhi Liu; Imelda Mercado-Uribe; Bin Chang; Xue Sherry Xiao; Jingfang Zheng; Feng-Xia Xue; Jinsong Liu
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

8.  Allelic loss at 19q12 and Xq11-12 predict an adverse clinical outcome in patients with mucinous ovarian tumours of low malignant potential.

Authors:  K Nakayama; Y Takebayashi; K Hata; R Fujiwaki; K Iida; M Fukumoto; K Miyazaki
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

9.  Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas.

Authors:  J M Arnold; S C Mok; D Purdie; G Chenevix-Trench
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

10.  Anti-cancer effects of Kaempferia parviflora on ovarian cancer SKOV3 cells.

Authors:  Suthasinee Paramee; Siriwoot Sookkhee; Choompone Sakonwasun; Mingkwan Na Takuathung; Pitchaya Mungkornasawakul; Wutigri Nimlamool; Saranyapin Potikanond
Journal:  BMC Complement Altern Med       Date:  2018-06-11       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.